Skip to main content

Table 2 Clinical, radiographic, and histologic features of 40 gangliogliomas stratified by genetic alterations

From: The genetic landscape of ganglioglioma

Clinicopathologic features BRAF V600E (n = 18) BRAF other alteration (n = 9) BRAF any alteration (n = 27) BRAF wildtype (n = 13) FGFR alteration (n = 5) Total cohort (n = 40)
Age (years), median (range)   15 (3–63) 17 (5–41) 15 (3–63) 32 (0–59) 35 (7–59) 21 (0–63)
Male: Female   13:5 2:7 15:12 8:5 3:2 23:17
Location: Cerebrum 13 (72%) 7 (78%) 20 (74%) 11 (85%) 5 (100%) 31 (78%)
  Cerebellum 3 (17%) 0 (0%) 3 (11%) 1 (8%) 0 (0%) 4 (10%)
  Thalamus 2(11%) 0 (0%) 2 (7%) 0 (0%) 0 (0%) 2 (5%)
  Spinal cord 0 (0%) 2 (22%) 2 (7%) 1 (8%) 0 (0%) 3 (8%)
Imaging features1
 Size (cm), median (range)   3.1 (2.0–5.9) 5.1 (1.8–7.1) 3.6 (1.8–7.1) 2.9 (1.3–16.0) 4.8 (1.3–9.6) 3.4 (1.3–16.0)
 Cystic component   9/11 (82%) 6/8 (75%) 15/19 (79%) 8/10 (80%) 3/4 (75%) 23/29 (79%)
 Well-circumscribed   3/11 (27%) 5/8 (63%) 8/19 (42%) 5/10 (50%) 2/4 (50%) 13/29 (45%)
Histologic features
 Glial component: Oligodendroglial 0 (0%) 0 (0%) 0 (0%) 3 (23%) 3 (60%)2 3 (8%)
  Astrocytic 18 (100%) 9 (100%) 27 (100%) 10 (77%) 2 (40%) 37 (92%)
 Eosinophilic granular bodies   13 (72%) 6 (67%) 19 (70%) 8 (62%) 3 (60%) 27 (68%)
 Rosenthal fibers   1 (6%) 1 (11%) 2 (7%) 4 (31%) 1 (20%) 6 (15%)
 Calcifications   9 (50%) 4 (44%) 13 (48%) 6 (46%) 3 (60%) 19 (48%)
 Perivascular lymphocytes   11 (61%) 8 (89%) 19 (70%) 4 (31%) 1 (20%) 23 (58%)
  1. 1Based on review of those cases (n = 29) with available pre-operative imaging studies
  2. 2Statistically significant difference (p = 0.001) between FGFR-altered tumors versus FGFR-wildtype tumors displaying oligodendroglial glial component (3/5 versus 0/35)